UNSPSC 51422331: Betamethasone valerate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9IFA5XM7R2, chemically known as 16-beta-methyl-1,4-pregnadiene-9-alpha-fluoro-11-beta,17-alpha,21-triol-3,20-dione but more generally known as betamethasone valerate, which bears US NIH Compound Identifier 9782.

The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, disodium phosphate, phosphate, sodium, sodium phosphate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, and 21-phosphate disodium.

UNSPSC 51422331 Betamethasone valerate is a Commodity code nominally covering a specific corticosteroid pharmaceutical product, but the recent state and local opportunities posted under this code show a significant mismatch with the code's intended scope. The two most recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer prescription program design — neither of which relates to betamethasone valerate or dermatological steroids. This code shows little relevant recent activity aligned with its pharmaceutical substance classification, suggesting either miscoding in source systems or a data-quality issue in how state and local procurement offices are classifying pharmaceutical purchases.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities around direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. Both solicitations involve pharmaceutical procurement at the state or county level, but neither involves the topical corticosteroid that the code nominally describes. The geographic spread evident in these two opportunities spans Florida and Texas, though the code shows insufficient recent activity to characterize broader regional concentration or issuing-body patterns. Business development professionals should verify UNSPSC coding accuracy before pursuing opportunities nominally tagged to this code, as the misalignment between code definition and actual solicitation scope limits its utility for targeted prospecting.